Инъекционные антипсихотики длительного действия при первом эпизоде шизофрении: клиническая перспектива (аналитический обзор)

Полный текст:
Читать

Рекомендуемое оформление библиографической ссылки:

Любов Е.Б. Инъекционные антипсихотики длительного действия при первом эпизоде шизофрении: клиническая перспектива (аналитический обзор) // Российский психиатрический журнал. 2013. №6. С. 59-69.

Аннотация

При недостатке доказательных данных эксперты рекомендуют пролонгированные инъекционные формы (депо) типичных (ТН) и, в большей мере, атипичных (АА) антипсихотиков, в основном рисперидон-конста и/или палиперидон пальмитат на ранних стадиях шизофрении. Раннее применение депо АА может снизить риск рецидива (регоспитализаций), улучшить социально-трудовую адаптацию больных и их качество жизни. Депо улучшают результаты лечения за счет комплайенса, особенно у пациентов с опытом эффекта пероральных форм тех же препаратов и согласных на такое лечение. Сочетанные преимущества AA с гарантированным обеспечением лечения позволяют рекомендовать депо в первом эпизоде психоза. Пока потенциал депо в повседневной практике использован недостаточно. Психиатрам следует пересмотреть свое негативное отношение к депо; важна их большая доступность.

Ключевые слова шизофрения; первый эпизод; инъекционные формы антипсихотиков длительного действия

Литература

1. Будза В.Г., Отмахов А.П., Прусс Г.Б. Отделение первого психотического эпизода - новая форма организации психиатрической помощи больным шизофренией // Соц. и клин. психиатрия. - 2005. - Т. 15, вып. 4. - С. 58-66. 2. Былим И.А., Любов Е.Б. Первый эпизод шизофрении: клинико-социальный и экономический эффекты целевой психосоциальной помощи // Психическое здоровье. - 2011. - № 1(56). - С. 60-65 3. Гурович И.Я., Любов Е.Б. Фармакоэпидемиология и фармакоэкономика в психиатрии. - М.: Медпрактика-М, 2003. - 264 с. 4. Киселев Л.С., Сочнева З.Г. Закономерности начала, течения и исходов основных психических заболеваний. - Рига: Зинатне, 1988. - 236 с. 5. Любов Е.Б. Проблема несоблюдения лекарственного режима в психиатрической практике // Соц. и клин. психиатрия. - 2001. - Т. 11, вып. 1. - С. 89-101. 6. Любов Е.Б. Рациональный выбор пролонгированной формы рисполепта конста: клиническое и фармакоэкономическое обоснование // Психиатрия и психофармакотер. - 2008. - Т. 10, Т 2. - С. 43-49. 7. Любов Е.Б. Палиперидон пальмитат - новая возможность фармакотерапии шизофрении // Соц. и клин. психиатрия. - 2011. - Т. 11, вып. 2. - С. 43-50. 8. Любов Е.Б., Бессонова А.А. Первый эпизод шизофрении: клинико-эпидемиологический и социально-экономический аспекты // Рос. психиатр. журн. - 2008. - № 2. - С. 46-50. 9. Любов Е.Б., Бугрова Е.И. Несоблюдение режима внебольничной психофармакотерапии больными шизофренией: клинико-социальные и экономические аспекты // Рос. психиатр. журн. - 2007. - № 5. - С. 65-70. 10. Первый психотический эпизод (проблемы и психиатрическая помощь) / Под ред. И.Я. Гуровича, А.Б. Шмуклера. - М.: МЕДПРАКТИКА-М, 2010. - 544 с. 11. Психиатрическая помощь больным шизофренией: клиническое руководство / Под ред. В.Н. Краснова и др. - 2-е изд. - М.: Медпрактика-М, 2007. - 260 с. 12. Addington J. Draft consеnsus statement-principles and practice in early psychosis // Implementing Early Intervention in Psychosis: a Guide to Establishing Early Psychosis Services / Eds J. Edwards, P. McGorry. - London: Martin Dunitz, 2002. - P. 145-155. 13. Adams C.E., Fenton M.K.P., Quraishi S., David A.S. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia // Br. J. Psychiatry. - 2001. - Vol. 179. - P. 290-299. 14. Aggarwal G., Dhawan S., Harikumar S.L. Formulation, in vitro, and in vivo evaluation of matrix-type transdermal patches containing olanzapine // Pharm. Develop. Technol. - 2011. - Vol. 2011, N 108374. 15. Aggarwal G., Dhawan S., Harikumar S.L. Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone // Drug Develop. Industr. Pharm. - 2012. - Vol. 2012, N 036390. 16. Аlvarez-Jimеnez M., Parker A.G., Hetrick S.E. et al. Preventing the Second Episode: A Systematic Review and Meta-Analysis of Psychosocial and Pharmacological Trials in First-Episode Psychosis // Schizophr. Bull. - 2011. - Vol. 37. - P. 619-630. 17. Amann L.C., Gandal M.J., Lin R. In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia // Pharm. Res. - 2010. - Vol. 27. - Р. 1730-1737. 18. Andreasen N.C., Carpenter W.T., Kane J.M. et al. Remission in schizophrenia: proposed criteria and rationale for consensus // Am. J. Psychiatry. - 2005. - Vol. 162. - P. 441-449. 19. Archie S., Hamilton Wiison J., Woodwardet K. et al. Psychotic Disorders Clinic and First-Episode Psychosis: A Program Evaluation // Can. J. Psychiatry. - 2005. - Vоl. 50. - Р. 46-51. 20. Argo T.R., Crimson M.L., Miller A.L. et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia. - The Texas Department of State Health Services, 2007. 21. Ascher-Svanum H., Peng X., Faries D. et al. Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients // BMC Psychiatry. - 2009. - Vol. 9. - P. 46. 22. Association CP. Clinical practice guidelines. Treatment of schizophrenia // Can. J. Psychiatry. - 2005. - Vоl. 50, suppl. 1. - Р. 7S-57S. 23. Barnes T.R., Shingleton-Smith A., Paton C. Antipsychotic longacting injections: prescribing practice in the UK // Br. J. Psychiatry. - 2009. Suppl. - Vol. 52. - S. 37-42. 24. Barnes T.R. Schizophrenia Consensus Group of British Association for Psychopharmacology Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology // J. Psychopharmacol. - 2011. - Vol. 25. - P. 567-620. 25. Barrio P., Batalla A., Castellvн P. et al. Effectiveness of longacting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study // Int. Clin. Psychopharmacol. - 2013. - Vol. 28, N 4. - P. 164-170. 26. Bartzokis G., Lu P.H., Amar C.P. et al. Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory // Schizophr. Res. - 2011. - Vol. 132, N 1. - P. 35-41. 27. Birchwood M., Todd P., Jackson C. Early intervention in psychosis. The critical period hypothesis // Br. J. Psychiatry. - 1998. - Vol. 172, suppl. 33. - P. 53-59. 28. Buchanan R.W., Kreyenbuhl J., Kelly D.L. et al. Schizophrenia Patient Outcomes Research Team (PORT): The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements // Schizophr. Bull. - 2010. - Vol. 36. - P. 71-93. 29. Chue P., Chue J. A review of paliperidone palmitate // Expert Rev. Neurother. - 2012. - Vol. 12. - P. 1383-1397. 30. Chue P., Emsley R. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics // CNS Drugs. - 2007. - Vol. 21. - P. 441-448. 31. Coldham E.L., Addington J., Addington D. Medication adherence of individuals with a first episode of psychosis // Acta Psychiatr. Scand. - 2002. - Vol. 106. - P. 286-290. 32. Crossley N.A., McGuire P., Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: metaanalysis // Br. J. Psychiatry. - 2010. - Vol. 196. - P. 434-439. 33. Cullberg J., Mattsson M., Levander S. et al. Treatment costs and clinical outcome for first episode schizophrenia patients: a 3-year follow-up of the Swedish "Parachute Project" and two comparison groups // Acta Psychiatr. Scand. - 2006. - Vоl. 114. - Р. 274-281. 34. Csernansky J.G., Schuchart E.K. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics // CNS Drugs. - 2002. - Vol. 16. - Р. 473-484. 35. Davis J.M., Chen N. Choice of maintenance medication for schizophrenia // J. Clin. Psychiatry. - 2003. - Vol. 64, suppl. 16. - P. 24-33. 36. Davis J.M., Metalon L., Watanabe M.D., Blake L. Depot antipsychotic drugs. Place in therapy // Drugs. - 1994. - Vol. 47. - P. 741-773. 37. Drake R.J., Haley C.J., Akhtar S., Lewis S.W. Causes and consequences of duration of untreated psychosis in schizophrenia // Br. J. Psychiatry. - 2000. - Vol. 177. - P. 511-515. 38. Eaton W.W., Thara R., Federman E., Tien A. Remission and relapse in schizophrenia: the Madras Longitudinal Study // J. Nerv. Ment. Dis. - 1998. - Vol. 186. - Р. 357-363. 39. Emsley R., Chiliza B., Asmal L., Harvey B.H. The nature of relapse in schizophrenia // BMC Psychiatry. - 2013. - Vol. 13. - P. 50. 40. Emsley R., Oosthuizen P., Koen L. et al. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies // Clin. Ther. - 2008. - Vol. 30. - P. 2378-2386. 41. Fleischhacker W.W. Second-generation antipsychotic long-acting injections: systematic review // Br. J. Psychiatry. - 2009. Suppl. - Vol. 52. - S29-S36. 42. Fraser R., Berger G., Killackey E., McGorry P. Emerging psychosis in young people - part 3 - key issues for prolonged recovery // Aust. Fam. Physician. - 2006. - Vol. 35. - P. 329-333. 43. Gaebel W., Riesbeck M., Wцlwer W. et al. Rates and predictors of remission in first-episode schizophrenia within 1year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia // Schizophr. Res. - 2013 S0920-9964(13)002120. doi: 10.1016/j.schres.2013.04.012. [Epub ahead of print] 44. Gass P., Mas S., Molina O. et al. Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells // Prog. Neuropsychopharmacol. Biol. Psychiatry. - 2012. - Vol. 36. - Р. 71-77. 45. Geerts P., Martinez G., Schreiner A. Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses // BMC Psychiatry. - 2013. - Vol. 13. - P. 58. 46. Gilbert P.L., Harris M.J., McAdams L.A., Jeste D.V. Neuroleptic withdrawal in schizophrenic patients // Arch. Gen. Psychiatry. - 1995. - Vol. 52. - P. 173-188. 47. Gitlin M., Nuechterlein K., Subotnik K.L. et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia // Am. J. Psychiatry. - 2001. - Vol. 158. - P. 1835-1842. 48. Glazer W.M., Kane J.M. Depot neuroleptic therapy: an underutilized treatment option // J. Clin. Psychiatry. - 1992. - Vol. 53. - P. 426-433. 49. Haddad P.M., Taylor M., Niaz O.S. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies // Br. J. Psychiatry. - 2009. - Vol. 195, suppl. 52. - P. s20-s28. 50. Hasan A., Falkai P., Wobrock T. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Pt 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects // World J. Biol. Psychiatry. - 2013. - Vol. 14. - P. 2-44. 51. Heres S., Reichhart T., Hamann J. et al. Psychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophrenia // Eur. Psychiatry. - 2011. - Vol. 26. - P. 297-301. 52. Hough D., Lindenmayer J.P., Gopal S. et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia // Prog. Neuropsychopharmacol. Biol. Psychiatry. - 2009. - Vol. 33. - P. 1022-1031. 53. Jaeger M., Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists // Psychiatry Res. - 2010. - Vol. 175, N 1-2. - P. 58-62. 54. Jeong H-G., Lee M.-S. Long-acting Injectable Antipsychotics in First-episode Schizophrenia // Clin. Psychopharmacol. Neurosci. - 2013. - Vol. 11. - P. 1-6. 55. Kahn R.S., Fleischhacker W.W., Boter H. et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial // Lancet. - 2008. - Vol. 371, N 9618. - P. 1085-1097. 56. Kane J.M. Treatment adherence and long-term outcomes // CNS Spectr. - 2007. - Vol. 12, suppl. 17. - P. 21-26. 57. Kane J.M., Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections // Br. J. Psychiatry. - 2009. - Vol. 195, suppl. - P. S63-S67. 58. Kim B., Lee S.H., Choi T.K. et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting // Prog. Neuropsychopharmacol. Biol. Psychiatry. - 2008. - Vol. 32. - P. 1231-1235. 59. iComparison of attitudes toward long-acting injectable antipsychotics among psychiatrists and patients // Int. Clin. Psychopharmacol. - 2013. - Vol. 28. - P. 80-86. 60. Kim S., Solari H., Weiden P.J., Bishop J.R. Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults // Patient Prefer Adherence. - 2012. - Vol. 6. - P. 533-545. 61. Kishimoto T., Robenzadeh A., Leucht C. et al. Long-Acting Injectable vs. Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials // Schizophr. Bull. - 2012. doi: 10.1093/schbul/sbs150 62. Kreyenbuhl J., Slade E.P., Medoff D.R. et al. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia // Schizophr. Res. - 2011. - Vol. 131, N 1-3. - P. 127-132. 63. Lacro J.P., Dunn L.B., Dolder C.R. et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature // J. Clin. Psychiatry. - 2002. - Vol. 63. - P. 892-909. 64. Lambert M., Conus P., Lambert T., McGorry P.D. Pharmacotherapy of first-episode psychosis // Expert Opin. Pharmacother. - 2003. - Vol. 4. - P. 17-50. 65. Lee S.H., Choi T.K., Suh S. et al. Effectiveness of a psychosocial intervention for relapse prevention in patients with schizophrenia receiving risperidone via long-acting injection // Psychiatr. Res. - 2010. - Vol. 175, N 3. - P. 195-199. 66. Lehman A.F., Lieberman J.A., Dixon L.B. et al. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. // Am. J. Psychiatry. - 2004. - Vol. 161, suppl. 2. - P. 1-56. 67. Leucht C., Heres S., Kane J.M. et al. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials // Schizophr. Res. - 2011. - Vol. 127, N 1-3. - P. 83-92. 68. Leucht S., Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia // J. Clin. Psychiatry. - 2006. - Vol. 67, suppl. 5. - P. 3-8. 69. Leucht S., Tardy M., Komossa K. et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis // Lancet. - 2012. - Vol. 379. - P. 2063-2071. 70. Lieberman J.A., Bymaster F.P., Meltzer H.Y. et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection // Pharmacol. Rev. - 2008. - Vol. 60. - P. 358-403. 71. Lieberman J.A., Perkins D., Belger A. et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches // Biol. Psychiatry. - 2001. - Vol. 50. - P. 884-897. 72. iPartial compliance in schizophrenia and the impact on patient outcomes // Psychiatr. Res. - 2008. - Vol. 161. - P. 235-247. 73. Love R.C. Strategies for increasing treatment compliance: the role of long- acting antipsychotics // Am. J. Health Syst. Pharm. - 2002. - Vol. 59, suppl. 8. - P. S10-S15. 74. Malla A., Binder C., Chue P. Comparison of long-acting injectable risperidone and oral novel antipsychotic drugs for treatment in early phase of schizophrenia spectrum psychosis // Proceedings of the 61st Annual Convention Society Biol. Psychiatry. - Toronto, 2006. 75. McEvoy J.P., Lieberman J.A., Perkins D.O. et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison // Am. J. Psychiatry. - 2007. - Vol. 164. - P. 1050-1060. 76. Mentschel C. Depot-drugs may reduce relapse rates in schizophrenic outpatients: a meta-analysis // Proceedings of the 156 th meeting of the American Psychiatric Association. - San Francisco, 2003. - P. 71. 77. Miller B.J. A review of second-generation antipsychotic discontinuation in first-episode psychosis // J. Psychiatr. Pract. - 2008. - Vol. 14. - P. 289-300. 78. Mojtabai R., Lavelle J., Gibson P.J. et al. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996 // Psychiatr. Serv. - 2002. - Vol. 53. - P. 337-339. 79. Naber D. Olanzapine pamoate for the treatment of schizophrenia // Expert Opin. Pharmacother. - 2011. - Vol. 12. - P. 627-633. 80. Nasrallah H.A. The case for long-acting antipsychotic agents in the post-CATIE era // Acta Psychiatr. Scand. - 2007. - Vol. 115, N 4. - P. 260-267. 81. National Institute for Health and Clinical Excellence (NICE) Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update), Final Version (NICE Clinical Guideline 82). NICE. - London, 2009 (http://www.nice.org.uk/CG82). 82. Nussbaum A.M., Stroup T.S. Paliperidone palmitate for schizophrenia // Cochrane Database Syst. Rev. - 2012: CD008296. 83. Olivares J.M., Alptekin K., Azorin J.-M. et al. Psychiatrists’ awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa // Patient Prefer Adherence. - 2013. - Vol. 7. - P. 121-132. 84. Parellada E., Velligan D.I., Emsley R. et al. Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia // Schizophr. Res. Treat. - 2012. - Vol. 2012, N 318535. - 3 p. 85. Patel M.X., Haddad P.M., Chaudhry I.B. et al. Psychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years // J. Psychopharmacol. - 2010. - Vol. 24. - P. 1473-1482. 86. Pereira S., Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication // Acta Psychiatr. Scand. - 1997. - Vol. 95. - Р. 464-468. 87. Perkins D.O., Gu H., Weiden P.J. et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, schizoaffective disorder: A randomized doubleblind, flexible-dose, multicenter study // J. Clin. Psychiatry. - 2008. - Vol. 69. - Р. 106-113. 88. Proctor S.E., Mitford E., Paxton R. First episode psychosis: a novel methodology reveals higher than expected incidence; a reality-based population profile in Northumberland, UK // J. Evaluat. Clin. Pract. - 2004. - Vol. 10. - Р. 539-547. 89. Robinson D., Woerner M.G., Alvir J.M. et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder // Arch. Gen. Psychiatry. - 1999. - Vol. 56. - P. 241-247. 90. Rooney K., Jones P., Sawh S. et al. Paliperidone palmitate efficacy and safety in the treatment of schizophrenia: a systematic review and meta-analysis // http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013004713 91. Rosenheck R.A., Krystal J.H., Lew R. et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia // N. Engl. J. Med. - 2011. - Vol. 364. - Р. 842-851. 92. Samalin L., Charpeaud T., Blanc O. et al. Clinicians’ attitudes toward the use of long-acting injectable antipsychotics // J. Nerv. Ment. Dis. - 2013. - Vol. 201. - P. 553-559. 93. Schooler N.R. Relapse and rehospitalization: comparing oral and depot antipsychotics // J. Clin. Psychiatry. - 2003. - Vol. 64, suppl. 16. - P. 14-17. 94. Sun D., Stuart G.W., Jenkinson M. et al. Brain surface contraction mapped in first-episode schizophrenia: a longitudinal magnetic resonance imaging study // Mol. Psychiatry. - 2009. - Vol. 14. - P. 976-986. 95. Svedberg B., Backenroth-Ohsako G., Lьtzйn K. On the path to recovery: patients’ experiences of treatment with long-acting injections of antipsychotic medication // Int. J. Ment. Health Nurs. - 2003. - Vol. 12, N 2. - P. 110-118. 96. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, “just the facts”: 4. Clinical features and conceptualization // Schizophr. Res. - 2009. - Vol. 110, N 1-3. - Р. 1-23. 97. Tiihonen J., Haukka J., Taylor M. et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia // Am. J. Psychiatry. - 2011. - Vol. 168. - P. 603-609. 98. Tourian L., Margolese H.C. Extended-release intramuscular aripiprazole for maintenance pharmacotherapy in schizophrenia and related disorders // Neuropsychiatry. - 2013. - Vol. 3, N 3. - P. 345-354. 99. Uсok A., Polat A., Сakir S. et al. One year outcome in first episode schizophrenia: Predictors of relapse // Eur. Arch. Psychiatry Clin. Neurosci. - 2006. - Vol. 256. - P. 37-43. 100. Valenstein M., Ganoczy D., McCarthy J.F. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review // J. Clin. Psychiatry. - 2006. - Vol. 67. - P. 1542-1550. 101. Velligan D.I., Weiden P.J., Sajatovic M. et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness // J. Clin. Psychiatry. - 2009. - Vol. 70, suppl. 4. - P. 1-46. 102. Verdoux H., Lengronne J., Liraud F. et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects // Acta Psychiatr. Scand. - 2000. - Vol. 102. - Р. 203 -210. 103. Viala A., Cornic F., Vacheron M.-N. Treatment Adherence with Early Prescription of Long-Acting Injectable Antipsychotics in Recent-Onset Schizophrenia // Schizophr. Res. Treat. - 2012. - Vol. 2012, N 368687. - 5 p. 104. Waddell L., Taylor M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review // Br. J. Psychiatry. - 2009. Suppl. - Vol. 195. - P. S43-50. 105. Walburn J., Gray R., Gournay K. et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication // Br. J. Psychiatry. - 2001. - Vol. 179. - P. 300-307. 106. Weiden P.J., Kozma C., Grogg A., Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia // Psychiatr. Serv. - 2004. - Vol. 55. - Р. 886-891. 107. Weiden P.J., Schooler N.R., Weedon J.C. et al. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study // J. Clin. Psychiatry. - 2012. - Vol. 73. - P. 1224-1233. 108. Wiersma D., Nienhuis F.J., Slooff C.J. et al. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort // Schizophr. Bull. - 1998. - Vol. 24. - Р. 75-85. 109. Yamada K., Watanabe K., Nemoto N. et al. Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study // Psychiatry Res. - 2006. - Vol. 141. - P. 61-69. 110. Zhornitsky S., Stip E. Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review // Schizophr. Res. Treat. - Vol. 2012, N 407171. - 12 p.

Метрики статей

Загрузка метрик ...

Metrics powered by PLOS ALM